Tongjitang Chinese Medicines Company to Announce First Quarter 2010 Financial Results on June 18, 2010

- Company to Hold Conference Call on June 21, 2010 at 8:00 am ET -

Jun 14, 2010, 16:01 ET from Tongjitang Chinese Medicines Company

SHENZHEN, China, June 14 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it plans to release its first quarter 2010 financial results after the market closes on Friday, June 18, 2010.

Tongjitang's management team will hold a conference call on Monday, June 21, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:

United States toll free:

1-888-287-5516

Hong Kong toll free:

800-968-103

Northern China toll free:

10-800-712-0046

Southern China toll free:

10-800-120-0046

International:

1-719-325-2101

Listeners may access the replay from approximately two hours after the call ends through June 28, 2010 by dialing the following numbers:

United States toll free:

1-888-203-1112

International:  

1-719-457-0820

Password:  

4613425

An audio webcast of the call will also be available through the Company's website at www.tongjitang.com.

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi.  In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit www.tongjitang.com for more information.

CONTACT

ICR, Inc.

Ashley M. Ammon or Christine Duan

203-682-8200 (Investor Relations)

SOURCE Tongjitang Chinese Medicines Company



RELATED LINKS

http://www.tongjitang.com